Skip to main content
. 2019 Aug 7;6:65. doi: 10.3389/fmolb.2019.00065

Table 1.

A summary of all CRC-related RBPs reviewed in this work: miRNAs control and their clinical relevance.

RBP Control by miRNAs Clinical relevance
LIN28 miR-let-7, miR-26a, miR-181, miR-9, miR-30, miR-125, miR-212 and miR-27 - Aberrant expression correlates with reduced patient survival.
- Predictive biomarker for chemotherapy.
MSI miR-137 - High expression correlates with increased metastatic risk and poorer survival.
- Promotes resistance to 5-FU.
ELAVL1 miR-519 and miR-22 - High expression correlates with malignancy and multidrug resistance.
QKI miR-574-5p and miR-155 - Low expression correlates with poorer prognosis.
- Could predict recurrence and prognosis.
RBM3 - Promotes resistance to chemotherapy
CELF1 miR-503
IGF2BPs - Overexpression correlates to unfavorable clinical outcomes: early dissemination, poor response to the therapy, increased tumor aggressiveness, and short survival.
ESRP1 - Overexpression associates with a favorable overall survival outcome.
TTP miR-29a - Downregulation correlates with poor prognosis, tumor aggressiveness, and necrosis.
hnRNPs - Poor prognosis marker.
TIA1 miR-19a - Increased numbers of TIA-1 positive TILs is associated with an improved clinical outcome.
- TIA1 can also be used to supplement prognostic information related to TNM stage and adjuvant therapy.
KHDRBS1 - KHDRBS1 nuclear localization and overexpression is correlated with poor tumor differentiation, advanced T stage, lymph node involvement, and distant metastasis.
CPEB4 miR-203 - Overexpression correlates with tumor progression and poor overall survival.
CSDE1 - Overexpression is associated to poor prognosis.